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Abstract 
Introduction: Whey protein contains biologically active ingredients that can
prevent and attenuate disease besides being nutritive. The aim of the study was
to clarify the effects of oral administration of whey protein on viral load and
host defence mechanisms, in particular, phagocytic function of neutrophils,
selected immunomodulatory cytokines and serum inflammatory markers, in
compensated chronic hepatitis C virus (HCV) patients. 
Material and methods: Twenty-seven HCV patients (20 males and 7 females)
recruited from the hepatology clinic of the Theodor Bilharz Research Institute
(TBRI) were given whey protein concentrate (WPC) twice daily for two months.
In addition, 15 age and sex matched healthy participants were included in the
study, as a control group. Neutrophil phagocytic activity, serum intercellular
adhesion molecule (sICAM), interleukin-2 (IL-2), nitric oxide (NO), as well as HCV-
RNA levels and routine investigations were determined for patients, before and
after WPC supplementation and once for the control group. 
Results: There was a significant decrease in viral load and markers of active
inflammation, alanine aminotransferase (ALT) and aspartate aminotransferase
(AST), while serum albumin, total leucocyte counts and absolute neutrophil
counts showed significant elevation accompanied by improvement of neutrophil
phagocytic activity after WPC supplementation compared to pre-treated levels.
The oral WPC supplementation was well tolerated without any serious adverse
events. 
Conclusions: Oral supplementation of WPC has promising results as a new
therapeutic strategy against HCV and its sequelae by decreasing the viral load
and active inflammation as well as improving the synthetic capacity of the liver
and the phagocytic function of neutrophils, in these patients.
Key words: whey protein, HCV, inflammatory markers, phagocytic function of
neutrophils.
Introduction
Hepatitis C virus (HCV) is a viral pandemic. About 200 mln individuals
worldwide are currently infected with HCV [1]. Egypt has a high seroprevalence
for HCV infection that reaches up to 20% in some rural areas [2]. 
It has been documented that the HCV genome is genetically very
unstable and mutates rapidly, leading to persistent viraemia and chronicity
in more than 80% of cases, despite the strong HCV-specific T-cell mediated
immune response [3]. Chronically infected patients often develop
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progressive liver disease from compensated to
decompensated state, cirrhosis, hepatic failure, and
hepatocellular carcinoma, making HCV infection the
first indication for liver transplantation [4]. Chronic
compensated hepatitis patients had relatively
normal ammonia tolerance and liver function tests.
On the other hand, decompensation was
characterized by abnormal ammonia tolerance and
liver function tests [5].
The treatment of chronic HCV with interferon
alpha (IFN-α) was initially introduced in 1985 and
marked a significant advance [6]. However, the
obtained response was not as high as expected
initially and combination therapy with pegylated
interferon and ribavirin has substantially enhanced
its efficacy up to 55% [7]. In spite of such progress,
this bitherapy has numerous side effects such as
neutropenia causing associated risk of bacterial
infections and sepsis, psychiatric and flu-like
symptoms, the existence of non-responders and
relapses besides being relatively expensive [8].
Earlier studies showed, in Africa and the Middle
East, prevalence of genotype 4 of C virus, which
frequently has a poorer response to conventional
interferon therapy than other genotypes [9].
Therefore, the need for the intervention of new
therapeutic agents, that activate host immunity, is
a challenge.
Whey protein concentrate (WPC) demonstrates
variable effects in HCV patients by correcting
decreased lymphocyte glutathione, found in these
patients, in order to activate the cell-mediated
immune function [10]. Its biological components, in
particular bovine serum albumin, alpha-lactalbumin
and lactoferrin, which are cysteine-rich proteins,
contribute to its potent antioxidant activity, by
aiding in the synthesis of glutathione (GSH),
a potent intracellular antioxidant, and demonstrate
a range of immune-enhancing properties [11].
This notion is supported, since 1980, by the
observation that normal mice fed on WPC as 20%
of a formula diet exhibited a marked increase in
antibody production in response to a T cell
dependent antigen [12]. Moreover, it has been
reported that the grade of activity of the liver
disease is correlated with the level of GSH. Also, the
effect of IFN was observed to be improved by
administering agents that restore the decrease of
GSH levels [13].
To evaluate the clinical efficacy and safety of
non-toxic dietary whey protein in compensated
chronic HCV patients, the present study was
designed to estimate the serum levels of ICAM-1,
IL-2, and NO as well as neutrophil count and its
phagocytic activity, liver functions and viral load,
before and after oral WPC supplementation, with
special emphasis on the statistical comparison
between the results of studied groups. 
Material and methods
Subjects
Twenty-seven patients, with compensated HCV
disease (20 males and 7 females), with an age range
of 22-60 years and a mean of 42.04 ±8.25 years,
were enrolled in the study. Patients were selected
from the hepatology clinic of TBRI, Egypt, who came
for evaluation of their chronic liver disease (CLD)
status between April 2006 and June 2007. 
Selection of patients at the time of recruitment
into the study was based on: proper history taking,
complete clinical examination, routine laboratory
investigations, in particular, elevated ALT for
a period more than 6 months to determine
chronicity, the presence of anti-HCV antibodies
(Abs) confirmed by HCV- RNA in serum and
screening abdominal ultrasonography.    
None of our patients had experienced signs of
decompensation such as ascites, jaundice,
gastrointestinal bleeding, flapping tremors or
encephalopathy. Special groups, including children,
patients with CLD other than HCV, patients either
having renal dialysis or with transplants and
patients who had received IFN treatment, are
beyond the scope of this study. Concerning non-
specific drugs for liver disease, mainly silymarin, or
similar drugs, the continued administration was
permitted if the dose was kept constant during the
study period. Given that, all patients enrolled in the
study were class A Child-Pugh according to the
classification of Pugh et al. in 1973 [14]. A group of
15 healthy subjects selected from the medical staff
and matched for age and sex served as the control
group. All subjects were informed about the study
and written consent was obtained from each one.
All procedures are according to the Helsinki
Declaration of 1975 as revised in 1983. 
Study design
The study was designed to supplement all
patients with WPC twice daily (morning and
evening) during meals or within 30 min after meals
for 8 weeks. To evaluate the efficacy of whey
protein, all investigations were performed before
and after supplementation for patients and once
for the controls. When treatment was discontinued
because of patient request, prior data were included
in the study as pre-treated results.
Preparation of whey protein concentrate
Sweet whey (pH 6.0-6.2) was obtained from Ras
cheese manufacture, Arab Dairy Co., Kaha, Kalubia,
Egypt. Fat and fine curd were removed from the
whey by a cream separator (Alfa-Laval Lund,
Sweden). Particulated whey protein concentrates
were prepared according to Paquin et al. [15] and El-
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Sheikh [16] by ultrafiltration of Ras cheese whey. The
gross characteristics of the particulated WPC were
determined: total solids (TS) according to AOAC [17];
total protein, fat and pH according to Ling [18];
lactose according to Barnett and Tawab [19]. After
preparation, WPC was packaged immediately in
glass bottles and kept in the refrigerator. The
ingredients of WPC are presented in Table I.
Assay methods
The following investigations were performed for
all patients immediately before WPC supplemen  -
tation and at the end of the supplement period 
(8 weeks) and once for the controls. Reference
ranges were provided by each manufacturer.
Routine investigations
All individuals enrolled in the study were
subjected to urine and stool analysis, and an
automated haemogram using Celtac MEK 8118
(Nihon Kohden, Japan). Blood smears were stained
with Leishman–Giemsa; differential leucocyte
counts were performed by counting 300 cells and
the absolute number of neutrophils was calculated.
PT and PC were done using a fibrin timer (Behring,
Germany). Liver function tests were carried out
using commercially available kits. HBsAg, anti-HBs
Abs and total IgM and IgG Abs for HBcAg were
determined using enzyme immunoassay (ELISA)
kits (Abbott laboratories, North Chicago, IL), to
exclude co-infection with HBV.  
Anti-HCV Abs were detected using a third
generation ELISA kit (Murex anti-HCV, Version III,
Murex Diagnostics, Dartford, England). Serum HCV-
RNA was determined by a quantitative reverse-
transcription polymerase chain reaction (RT-PCR).
HCV was extracted using acid guanidinium
thiocyanate-phenol chloroform single step method
[20]. Two pairs of primers in the 5’ untranslated
region (UTR) were used in the nested reaction as
described previously by Matsumoto et al [21]. The
sensitivity level of this assay is 50 IU/ml.
Special investigations
Determination of nitric oxide
Heparinized blood samples were centrifuged and
the plasma collected then filtered through a 1.2 µm
MultiScreen filter plate (Millipore, Bedford, MA).
Plasma NO concentrations were determined using
the Griess reaction as described previously by Ding
and Rana [22] with the following modification. 
Six µl of plasma were mixed with 135.44 µl of H2O,
20 µl of 0.31 M phosphate buffer (pH 7.5) and 
10 µl of 0.86 mM nicotine adenine dinucleotide
phosphate (Boehringer Mannheim Corp., New York,
NY), 10 µl of 0.11 mM flavin adenine dinucleotide
(Sigma) and 10 µl of nitrate reductase (1.0 U/ml)
(Boehringer Mannheim Corp.) in individual wells of
a 96-well plate. Samples were allowed to incubate
for 1 hr at room temperature in the dark. One
hundred µl of Griess reagent (1 : 1 mixture of 1%
sulfanilamide [Sigma] in 5% H3PO4 and 0.1% 
N-[1-naphthyl] ethylenediamine [Sigma]) was added
to each well and plates were incubated for an
additional 10 min at room temperature. Absorbance
was measured at 540 nm using a microplate reader.
Determination of sICAM-1 
Serum ICAM-1 levels were assayed by sandwich
ELISA technique (Immunotech, France) according
to the manufacturer's instructions. Each sample was
assayed in duplicate.
Determination of IL-2
EDTA anticoagulated samples were used to avoid
in vitro production of cytokines because EDTA acts
as a chelating agent. IL-2 was performed using
a commercially available ELISA kit (Predicta, Human
Cytokine Assays).
Nitroblue-tetrazolium test
Unstimulated nitroblue-tetrazolium test (NBT) test
was performed immediately or within 2 h at 4°C
using heparinized blood. Briefly, 0.1% NBT was
prepared in PBS by adding 10 mg of NBT powder
(Sigma, St Louis) to 100 ml of PBS (pH 7.2) and stirred
at room temperature for 1 h. The NBT staining was
done for neutrophils after their separation using
dextran sedimentation [23] as follows: (i) Equal
volumes of 0.1% NBT solution and cell suspension
were mixed and incubated for 30 min at 37°C. 
(ii) The tubes were centrifuged at 250 × g for 5 min.
(iii) Smears were prepared from the pellet and
stained after drying with Wright stain, and then
scoring cells containing formazan deposits (reduced
NBT) was performed by counting 200 neutrophils as
described by Baehner and Nathan [24].
Statistical analysis
Statistical analysis was performed using SPSS
version 16 software. Results, presented as mean 
± standard deviation and percentages, were
compared using one-way analysis of variance
Ingredients Content
Total solids [%] 18.24
Total protein [%] 15.08
Lactose [%] 1.22
Fat [%] 1.05
PH 7.08
Table I. Composition of the whey protein concentrate
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(ANOVA) and Scheffé's method for comparisons
between groups. The data were considered
significant when p < 0.05. Statistical analysis
between pre- and post-WPC intake was performed
using the paired t test.
Results 
Twelve patients out of 27 who had started
receiving WPC oral supplementation completed the
test period (8 weeks). The causes of discontinuation
among the 15 subjects were: nausea and vomiting
in 5 patients, diarrhoea and abdominal discomfort
in 2 patients and 8 patients preferred shifting to
interferon-based therapy. Hence, after performance
of the study, the enrolled subjects were classified
into: a pre-treated group of patients (group A, 
n = 27) and a post-treated group (group B, n = 12)
in addition to the control group (n = 15).
Routine investigations indicated significant
reduction of PT, PC% and total leucocyte counts
(Table II), besides absolute neutrophil counts 
(Table III), in the patient groups compared to control
subjects. Although WPC treatment did not change
these parameters, significant improvement of
neutrophil phagocytic activity was noticed (Table III).
The HCV-RNA results, presented in Table IV, show
a statistically significant reduction comparing group
B with A. In addition, 2 patients had undetected
viraemia after WPC treatment. Results of screening
liver function tests pointed to a significant rise of
albumin and reduction of ALT and AST in group B.
Although albumin was normalized after 8 weeks of
treatment with WPC, both enzymes were still
significantly higher than normal. As regards the
results of parameters of active inflammation,
a significant reduction of the 3 parameters (sICAM-1,
IL-2 and NO) was recorded in group B. However,
after WPC supplementation, all 3 parameters were
still significantly higher than control subjects, as
shown in Table IV. 
Parameter  Group 
Control groupP atients groups
Group AG roup B
Number of patients 15 27 12
Gender: male/female ratio 3/2 2/1 3/1
Age [years] 43.1 ±9.7 41.2 ±7.3 42.4 ±9.3
Child-Pugh class (A) percentage 0 100 100
PT [sec] 11.7 ±0.22 15.1 ±2.87* 14.7 ±1.98*
PC [%] 96.2 ±3.01 63.9 ±17.5* 62.7 ±16.9*
Hb [g/dl] 13.52 ±1.42 11.05 ±1.12 11.2 ±2.11
RBCs [× 1012/l] 4.73 ±0.67 3.87 ±0.52 3.86 ±0.63
Platelet count [× 109/l] 268.42 ±55.05 165.25 ±58.65 166.1 ±38.9
Total leucocytic count [× 109/l] 7.7 ±1.78 5.22 ±1.98* 6.08 ±1.1*
Data were expressed as mean ± SD or as percent value, *statistically significant from the control group. Group A – pretreated group, 
Group B – post-treated group, PT – prothrombin time, PC – prothrombin concentration, Hb – heamoglobin concentration, RBCs – red blood cells
Table II. Demographic and clinical, characteristics of different studied groups 
Parameter  Group 
Control group  Patients groups
(n = 15) Group A (n = 27) Group B (n = 12)
Total leucocytic count [× 109/l] 7.7 ±1.78 5.22 ±1.98* 6.08 ±1.1*
Absolute neutrophil count [× 109/l]  3.9 ±0.9 1.8 ±1.98* 2.1 ±0.86*
Percentage of unstimulated NBT+ve  8.7 6.7 8.3 
neutrophils [%]
Absolute unstimulated NBT+ve  0.33 ±0.017 0.12 ±0.012* 0.17 ±0.0094*#
neutrophils [× 109/l]
Group A – pretreated group, Group B – post-treated group, NBT +ve – nitroblue tetrazolium positive, *statistically significant from the control
group, #statistically significant from the pretreated group
Table III. Total leucocytic and absolute neutrophil counts and phagocytic activity in the studied groups
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Discussion
Conventional hepatitis C therapy focuses on
reducing the viral load, while it does nothing to
address the ongoing liver damage caused by the
virus [25].
In this study we tried to elucidate the efficacy of
WPC in treatment of HCV infection. To achieve this
goal, the present work monitored the liver status
and viral load, in addition to selected immunological
and haematological parameters, in compensated
chronic HCV patients on comparing the pre- with
the post-treated results.
Based on published clinical studies, it has been
demonstrated that monitoring viral load during the
early phases of treatment may provide early
information on the likelihood of a response to
antiviral therapy [26]. In the present study when
comparing the pre- and post-treated groups (A and
B), a virological response (a 50% or greater decrease
in HCV RNA level) was achieved in 8 out of the 12
patients belonging to group B. Of these 8 patients,
2 subjects had undetectable levels of HCV RNA at
the end of the test period. It has to be noted that
the 4 patients whose viral load did not decline
appropriately after the 8-week oral course of 
WPC had a higher pre-treated level than the 
other patients. It appears that whey protein
administration may be more rapidly effective in the
case of a low pre-treated viral load. Higher viral
loads would need longer courses. 
Conversely, WPC intake for 8 weeks did not have
a favourable effect on the serum ALT level, as only
4 out of 12 studied subjects (about 33%) reached
the level of a biochemical response (a 50% or
greater decrease in the serum ALT level). This may
be related to the fact that our studied subjects had
an ALT baseline only about 4 times the control
level. Subsequently, the ALT decline seemed to
approach the normal level to a certain extent
without fulfilling the biochemical response.
Eventually, however, on comparing pre- to 
post-treated groups, there was a significant
reduction in the viral load and the ALT level. 
In agreement with our results, Tanaka et al. [27]
has demonstrated in his pilot study among 11 patients
having low pre-treated viral loads of HCV, and
receiving daily bovine lactoferrin, for 8 weeks,
a decrease in HCV-RNA and ALT compared to those
having higher pre-treated HCV loads. Conversely, in
a study conducted among 17 HCV patients who
received 12 g of whey (Immunocal) twice daily for
12 weeks, preceded and followed by 12 g of casein
protein daily for two weeks and four weeks
respectively, no significant changes were noted [7].
These conflicting results may be attributed to the
selected criteria of the studied patients, particularly
viral load baseline and the HCV genotype
prevalence.
Post-treated results revealed that albumin was
significantly increased, while, for PT, insignificant
improvement was noticed, which may suggest 
the need for longer oral course duration. 
The improvement in albumin level, reaching the
level of normal control subjects, indicates positive
nitrogen balance, which is a good achievement,
as malnutrition is a cause of many of the
complications of chronic liver disease. We assume
that hypoalbuminemia met in our patients was
due to decreased hepatic synthesis, not
a consequence of losing capacity, as none of our
patients suffered from diarrhoea, proteinuria or
nutritional disorders. 
Whey protein concentrate provides all essential
amino acids and is rich in branched-chain amino
acids (BCAAs), which are important factors in tissue
growth and repair [7]. Leucine, in particular, has
been identified as a key amino acid in protein
metabolism during the translation-initiation of
protein synthesis [28]. Moreover, whey proteins,
“fast proteins” do not coagulate under acidic
Parameter  Group 
Control group  Patients groups
(n = 15) Group A (n = 27) Group B (n = 12)
HCV-RNA [10n copy/ml] Undetected 18.7 x 104 3.75 x 104#
Albumin [g/dl] 4.4 ±0.52 3.1 ±0.38* 4.20 ±0.32#
ALT [IU/l] 10.1 ±1.81 47.5 ±7.01* 30.5 ±3.34*#
AST [IU/l] 10.13 ±1.08 36 ±6.87* 28.9 ±5.7*#
sICAM-1 [ng/ml] 230.0 ±11.00 877.3 ±335*  555.8 ±218.8*#
IL-2 [pg/ml] 6.9 ±1.10 34.6 ±1.8* 26.5 ±2.6*#
NO [µmol/l] 32.17 ±2.19 76.36 ±8.11* 54.34 ±11.95*#
Data were expressed as mean ± SD or as (copy n/ml), *statistically significant from the control group, #statistically significant from the pretreated
group, P-values refer to paired t-test (before & after vs. control), Group A – pretreated group, Group B – post-treated group 
Table IV. Results of viral load, biochemical and inflammatory markers in studied groups
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conditions. They reach the jejunum quickly after
entering the gastrointestinal tract, where the
hydrolysis of whey is slow, allowing for greater
absorption over the length of the small intestine [13].
Taken together, the above-mentioned properties
of whey protein, with correction of malnutrition
frequently observed in CLD patients, improves the
clinical outcome of these patients.
Earlier studies showed that sICAM-1 is correlated
with degree of active inflammation and histo  -
pathological activity [29]. Subsequently, it can be
considered as a useful marker of hepatocellular
necrosis and inflammatory activity in chronic
hepatitis and has prognostic significance in cirrhotic
patients [30].
The obtained data revealed a significant
elevation of sICAM-1, IL-2 and NO levels in
diseased groups A and B compared to the control
group, while a significant decrease was observed
on comparing group B to A. In addition, correlation
studies showed that sICAM-1 was directly
correlated with the viral load in group A and
inversely correlated with serum albumin in group B.
Therefore, a reducing effect of WPC on sICAM-1
and viral load accompanied by improvement of
the liver status of HCV patients was recorded, 
as indicated by increasing serum albumin,
considered as a monitor of the synthetic capacity
of the liver. 
Our findings are consistent with those of Capra
et al. [30] and Montalto et al. [31] as regards sICAM-1
after IFN treatment of HCV patients and for IL-2 in
other studies [32, 33]. In contrast to our IL-2 results,
Zekri et al. [9] reported insignificant changes in
serum IL-2 measurements in chronic HCV patients.
The authors attributed this finding to the presence
of soluble receptor (sIL-2R) binding to IL-2. 
The NO increase during the course of HCV
infection is explained by Machida et al. [34]. They
reported that the viral core and NS3 proteins can
stimulate the production of NO in hepatocytes and
B cells through activation of the inducible NO
synthase (iNOS) gene. NO causes DNA breaks and
enhances DNA mutation and subsequently is
correlated with the severity of the disease [35].
A recent study conducted on rats injected with
whey protein (300 mg/kg) revealed that alpha-
lactalbumin has a marked suppressive effect on
pro-inflammatory cytokine release, particularly 
IL-6, through an NO-mediated mechanism [36].
Increased susceptibility to recurrent and serious
bacterial infections is a common association in CLD
[37], which in turn is due to impairment of
phagocytic function of neutrophils and natural killer
cell activity of lymphocytes among these patients
[38]. Data obtained from the present study revealed
a significant decrease in total leucocyte, absolute
neutrophil and NBT +ve neutrophil counts in
diseased groups compared to the control one. 
On comparing pre- and post-treated groups,
a significant increase in number of absolute NBT
+ve neutrophils was found in the post-treated
group. Considering NBT as an indicator of the
phagocytic activity of neutrophils, the present
results agree with several studies [39, 40].
Nakamura et al. [38] concluded that phagocytic
function of neutrophils was significantly improved
by 3 month-BCAA supplementation, although
changes of albumin level were insignificant.
Studies on whey protein, in particular its
contents of lactoferrin, and alpha-lactalbumin, have
demonstrated its ability to activate natural killer
(NK) cells and neutrophils by intracellular
replenishment of depleted glutathione [13]. Also,
lactoferrin has antiviral properties, through its iron
chelating properties. Several studies have revealed
that hepatitis C inflicts most of its damage by
latching onto molecules of iron, resulting in free-
radical damage to liver cells. Despite substantial
scientific evidence, few physicians implement iron-
depletion therapy when treating hepatitis C [41].
Meanwhile, neutrophils have been shown by RT-
PCR to be among the extra-hepatic sites of HCV
replication [42]. Hence, the significant improvement
of NBT +ve cells in the post-treated group and the
increased absolute neutrophil count, although not
to a significant level, recorded in this work indicate
a beneficial effect of WPC mainly on the qualitative
and to a lesser extent on the quantitative status of
neutrophils among HCV patients. 
Finally, our present trial left many unanswered
questions for future studies, including optimum
dose, duration, and the potential effects of
combining WPC supplementation with conventional
treatment. In addition, the effects of whey protein
administration and its long-term use on prognosis
of patients with high pre-treated viral loads,
advanced stages of liver disease and in hepatocarci  -
no  genesis remain to be investigated in the future. 
In conclusion, WPC supplementation showed
promising results among compensated hepatitis C
virus patients. It has a viral load reducing effect,
accompanied by normalization of serum albumin
and improvement of phagocytic function of
neutrophils, at the end of an 8-week oral course.
These responses were paralleled with a significant
decrease in serum levels of ALT, ICAM-1, IL-2 and
NO. Presumably, WPC administration provides
nutrition which could positively affect the prognosis
of the patients. Also, it is well tolerated and shows
no side effects like those of conventional therapy.
Hence, we recommend trying this supplementation
as an adjuvant to interferon therapy or as an
alternative for non-responders. Prospective studies
are needed to enlighten these postulations.
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